{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:09:28Z","timestamp":1791230968467,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.vaccine.2024.126511","type":"journal-article","created":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T03:55:16Z","timestamp":1731210916000},"page":"126511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"P2","title":["Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX\/COVID-12 \u201cPatria\u201d recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico"],"prefix":"10.1016","volume":"43","author":[{"given":"Constantino","family":"L\u00f3pez-Mac\u00edas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Armenta-Copca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels H.","family":"Wacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Castro-Castrezana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Alicia","family":"Colli-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Rivera-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Torres-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Dami\u00e1n-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ram\u00edrez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina Paz-De","family":"la Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Rojas-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Su\u00e1rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Peralta-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Carranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmeralda","family":"Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Zamudio-Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Carreto-Binaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Viettri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damaris","family":"Romero-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Reyna-Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 E.","family":"M\u00e1rquez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sarfati-Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor El\u00edas","family":"Chagoya-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipa","family":"Castro-Peralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Palese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Lozano-Dubernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"372","key":"10.1016\/j.vaccine.2024.126511_bb0015","first-page":"1392","article-title":"Hybrid immunity","volume":"2021","author":"Crotty","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.126511_bb0020","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/infdis\/jiad353","article-title":"SARS-CoV-2 hybrid immunity: the best of both worlds","volume":"228","author":"Lasrado","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126511_bb0025","first-page":"8","article-title":"Breakthrough infections, hospital admissions, and mortality after major COVID-19 vaccination profiles: a prospective cohort study","author":"Wichaidit","year":"2023","journal-title":"Lancet Regional Health - Southeast Asia"},{"key":"10.1016\/j.vaccine.2024.126511_bb0040","first-page":"1","article-title":"Mice immunized with the vaccine candidate hexapro spike produce neutralizing antibodies against sars-cov-2","volume":"9","author":"Seephetdee","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.126511_bb0045","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.126511_bb0050","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/vaccines10040578","article-title":"Dermal Delivery of a SARS-CoV-2 Subunit Vaccine Induces Immunogenicity against Variants of Concern","volume":"10","author":"McMillan","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2024.126511_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-30222-w","article-title":"Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants","volume":"13","author":"Kang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126511_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-26499-y","article-title":"A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126511_bb0065","first-page":"12","article-title":"Safety and immunogenicity of a Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate, AVX\/COVID-12-HEXAPRO (patria)","author":"Lara-Puente","year":"2021","journal-title":"Pigs MBio"},{"key":"10.1016\/j.vaccine.2024.126511_bb0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41541-023-00662-6","article-title":"Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico","volume":"8","author":"Ponce-de-Le\u00f3n","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2024.126511_bb0075","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/jama.2020.20892","article-title":"Herd immunity and implications for SARS-CoV-2 control","volume":"324","author":"Omer","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2024.126511_bb0080","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/infdis\/jir661","article-title":"Influenza Hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection","volume":"204","author":"Ohmit","year":"2011","journal-title":"J Infect Dis"},{"issue":"375","key":"10.1016\/j.vaccine.2024.126511_bb0085","first-page":"43","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"2022","author":"Gilbert","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.126511_bb0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.32760","article-title":"Estimated effectiveness of COVID-19 vaccines against omicron or Delta symptomatic infection and severe outcomes","volume":"5","author":"Buchan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2024.126511_bb0095","first-page":"19","article-title":"Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: a systematic review","author":"Paul","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.126511_bb0100","article-title":"Real-world effectiveness of BNT162b2 in children and adolescents","author":"Wu","year":"2023","journal-title":"MedRxiv"},{"key":"10.1016\/j.vaccine.2024.126511_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-35168-7","article-title":"Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England","volume":"13","author":"Kirsebom","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2024.126511_bb0110","doi-asserted-by":"crossref","first-page":"85","DOI":"10.21149\/15125","article-title":"The Omicron wave in Mexico: vaccine protection against progression to severe Covid-19 in SARS-CoV-2-infected workers","volume":"66","author":"Hern\u00e1ndez-\u00c1vila","year":"2024","journal-title":"Salud Publica Mex"},{"issue":"7821","key":"10.1016\/j.vaccine.2024.126511_bb0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"issue":"372","key":"10.1016\/j.vaccine.2024.126511_bb0120","first-page":"1413","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"2021","author":"Stamatatos","year":"1979","journal-title":"Science"},{"issue":"372","key":"10.1016\/j.vaccine.2024.126511_bb0125","first-page":"1418","article-title":"Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose","volume":"2021","author":"Reynolds","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2024.126511_bb0130","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02250-23","article-title":"The post-COVID-19 population has a high prevalence of cross-reactive antibodies to spikes from all Orthocoronavirinae genera","author":"Singh","year":"2024","journal-title":"MBio"},{"key":"10.1016\/j.vaccine.2024.126511_bb0135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2020.12.009","article-title":"T cell memory: understanding COVID-19","volume":"54","author":"Jarjour","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2024.126511_bb0140","article-title":"BNT162b2 vaccination induces durable SARS-CoV-2\u2013specific T cells with a stem cell memory phenotype","volume":"6","author":"Guerrera","year":"2023","journal-title":"Sci Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24011939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24011939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T03:21:11Z","timestamp":1734492071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24011939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":24,"alternative-id":["S0264410X24011939"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126511","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX\/COVID-12 \u201cPatria\u201d recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126511"}}